RxDoctor Payments Data

Meagan Carroll, APRN

Gerontology · Fairfield, CTNPI 1346750510

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 37.0% of the total. 2025 is the largest year on record at $666, 7.4 times the $91 reported in 2021.

$1,502in general payments, 2019–2025

Across 79 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556
  • Amgen$152
  • GSK$144
  • Novo Nordisk$143
  • AstraZeneca$90
  • Pfizer$83
  • plus $335 from 6 others

What the payments were for

  • Food & beverage$1,502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,502 in reported general payments places this provider in the 80th percentile of 90 gerontology providers in Connecticut.

See all gerontology providers in Connecticut

Medicare billing

Part B allowed, 2024
$83,993
Medicare patients
238
Services billed
1,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$22,115
MounjaroTirzepatide19$20,015
FarxigaDapagliflozin Propanediol11$11,236
Lagevrio (Eua)Molnupiravir17$3,886
Atorvastatin Calcium69$558
Levothyroxine Sodium47$540
Albuterol Sulfate HfaAlbuterol Sulfate24$499
Gabapentin16$454
Fluticasone Propionate27$416
Amlodipine Besylate71$409
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$362
Nebivolol Hcl12$355
Duloxetine Hcl11$351
Metoprolol Succinate33$328
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$143$22,11517 claims
Lilly USA, LLCMounjaro$48$20,01519 claims
AstraZenecaFarxiga$90$11,23611 claims
MerckLagevrio (Eua)$18$3,88617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 gerontology providers in Connecticut.

Other gerontology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →